CETP inhibition, statins and diabetes. (November 2018)

• Record Type: Journal Article
• Authors: Barter, Philip J.; Cochran, Blake J.; Rye, Kerry-Anne
• Is Part Of: Atherosclerosis. Volume 278(2018)
• Page Start: 143
• Page End: 146
• Publication Date: 2018-11
• Subjects: CETP inhibition -- Statins -- Diabetes; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2018.09.033
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Type 2 diabetes is a causal risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). While treatment with a statin reduces the risk of having an ASCVD event in all people, including those with type-2 diabetes, statin treatment also increases the likelihood of new onset diabetes when given to those with risk factors for developing diabetes. Treatment with the cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, reduces the risk of having a coronary event over and above that achieved with a statin. However, unlike statins, anacetrapib decreases the risk of developing diabetes. If the reduced risk of new-onset diabetes is confirmed in another CETP inhibitor outcome trial, there will be a case for considering the use of the combination of a statin plus a CETP inhibitor in high ASCVD-risk people who are also at increased risk of developing diabetes. Highlights: Treatment with a statin increases the likelihood of new onset diabetes. Treatment with a CETP inhibitor reduces risk of new onset diabetes.